Exploring the neuroprotective, antioxidant, and anti-amyloid effects of Ganoderma lucidum compounds in Alzheimer’s disease: insights from experimental and computational approaches
Mojnu Mia, Amit Dutta, Md Mainuddin Hossain, Juthi Adhikari, Md Masuder Rahman, Abu Zaffar Shibly · 2026
Read Exploring the neuroprotective, antioxidant, and anti-amyloid effects of Ganoderma lucidum compounds in Alzheimer’s disease: insights from experimental and computational approaches by Mojnu Mia, Amit Dutta, Md Mainuddin Hossain, Juthi Adhikari, Md Masuder Rahman, Abu Zaffar Shibly (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13213306.txt.
Description
Mojnu Mia and co-authors test a medicinal mushroom against Alzheimer hallmarks in worms and computer models. Their 2026 study studies Ganoderma lucidum, rich in triterpenoids and sterols. Lab assays, worm tests, and docking simulations share the work.
The extract scavenges radicals strongly at low dose. Worms under oxidative stress survive about a quarter longer on treatment. Amyloid-driven paralysis in a worm strain is delayed, with some worms still active at sixty-eight hours. Docking names three compounds as strong amyloid binders, and dynamics runs keep those bonds stable. Energy sums confirm tight binding for the lead compound. Drug-likeness predictions look clean, with good gut absorption and no flagged toxicity. The authors back the mushroom as a multi-path candidate.
Catalog record
| CREATOR | Mojnu Mia, Amit Dutta, Md Mainuddin Hossain, Juthi Adhikari, Md Masuder Rahman, Abu Zaffar Shibly |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 61 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |